Catalent, Inc. (NYSE:CTLT) Receives $59.83 Average Target Price from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $59.83.

Several brokerages have recently issued reports on CTLT. StockNews.com started coverage on shares of Catalent in a research report on Saturday. They set a “hold” rating for the company. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th.

Insiders Place Their Bets

In related news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,410 shares of company stock valued at $732,680. 0.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalent

Several institutional investors and hedge funds have recently bought and sold shares of CTLT. V Square Quantitative Management LLC grew its position in Catalent by 34.0% in the fourth quarter. V Square Quantitative Management LLC now owns 5,332 shares of the company’s stock valued at $240,000 after acquiring an additional 1,352 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Catalent during the fourth quarter worth $432,000. Royal London Asset Management Ltd. lifted its stake in shares of Catalent by 5.0% in the 4th quarter. Royal London Asset Management Ltd. now owns 63,727 shares of the company’s stock valued at $2,863,000 after acquiring an additional 3,041 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of Catalent during the 1st quarter valued at $52,000. Finally, Clearview Wealth Advisors LLC bought a new stake in Catalent during the 1st quarter worth $356,000.

Catalent Stock Up 0.0 %

Catalent stock opened at $60.66 on Friday. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The firm has a market capitalization of $10.98 billion, a price-to-earnings ratio of -9.93, a PEG ratio of 2.14 and a beta of 1.15. The company’s 50 day simple moving average is $60.06 and its 200 day simple moving average is $57.68.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. As a group, sell-side analysts anticipate that Catalent will post 0.95 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.